[go: up one dir, main page]

ES2065691T3 - Derivados de quinuclidina. - Google Patents

Derivados de quinuclidina.

Info

Publication number
ES2065691T3
ES2065691T3 ES91909987T ES91909987T ES2065691T3 ES 2065691 T3 ES2065691 T3 ES 2065691T3 ES 91909987 T ES91909987 T ES 91909987T ES 91909987 T ES91909987 T ES 91909987T ES 2065691 T3 ES2065691 T3 ES 2065691T3
Authority
ES
Spain
Prior art keywords
quinuclidine derivatives
quinuclidine
derivatives
pain
formulas
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91909987T
Other languages
English (en)
Inventor
John A Lowe Iii
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Corp Belgium
Pfizer Corp SRL
Original Assignee
Pfizer Corp Belgium
Pfizer Corp SRL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Corp Belgium, Pfizer Corp SRL filed Critical Pfizer Corp Belgium
Application granted granted Critical
Publication of ES2065691T3 publication Critical patent/ES2065691T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Control Of Electric Motors In General (AREA)
  • Soft Magnetic Materials (AREA)
  • Paper (AREA)

Abstract

LOS DERIVADOS DE LA QUINUCLIDINA CON LAS FORMULAS (I), (II) O (III) Y SUS SALES FARMACEUTICAMENTE ACEPTABLES, EN DONDE M, P, Z, Y, R1, R2 Y R3 SON LO DEFINIDO MAS ABAJO. LOS COMPUESTOS SON ANTAGONISTAS P DE SUBSTANCIAS Y, POR LO TANTO, SON UTILES EN EL TRATAMIENTO DE DESORDENES GASTROINTESTINALES, DESORDENES DEL SISTEMA NERVIOSO CENTRAL, ENFERMEDADES INFLAMATORIAS, EL DOLOR Y LAS MIGRAÑAS.
ES91909987T 1990-07-23 1991-05-14 Derivados de quinuclidina. Expired - Lifetime ES2065691T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US55744290A 1990-07-23 1990-07-23

Publications (1)

Publication Number Publication Date
ES2065691T3 true ES2065691T3 (es) 1995-02-16

Family

ID=24225412

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91909987T Expired - Lifetime ES2065691T3 (es) 1990-07-23 1991-05-14 Derivados de quinuclidina.

Country Status (25)

Country Link
US (5) US5422354A (es)
EP (1) EP0540526B1 (es)
JP (1) JP2514137B2 (es)
CN (1) CN1058405A (es)
AT (1) ATE116317T1 (es)
AU (1) AU660416B2 (es)
BR (1) BR9106665A (es)
CA (1) CA2086434C (es)
DE (1) DE69106365T2 (es)
DK (1) DK0540526T3 (es)
ES (1) ES2065691T3 (es)
FI (1) FI114473B (es)
GR (1) GR3015144T3 (es)
HU (1) HUT62584A (es)
IE (1) IE65000B1 (es)
IL (1) IL98860A (es)
MX (1) MX9100308A (es)
MY (1) MY107157A (es)
NO (1) NO302172B1 (es)
NZ (1) NZ239063A (es)
PL (1) PL167568B1 (es)
PT (1) PT98393B (es)
WO (1) WO1992001688A1 (es)
YU (1) YU128091A (es)
ZA (1) ZA915727B (es)

Families Citing this family (76)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE116317T1 (de) * 1990-07-23 1995-01-15 Pfizer Chinuclidinderivate.
US5716965A (en) * 1991-05-22 1998-02-10 Pfizer Inc. Substituted 3-aminoquinuclidines
HU221634B1 (hu) * 1991-06-20 2002-12-28 Pfizer Inc. Nitrogéntartalmú heterociklusos vegyületek fluor-alkoxi-benzilamino-származékai, eljárás előállításukra és az ezeket tartalmazó gyógyszerkészítmények
TW202432B (es) * 1991-06-21 1993-03-21 Pfizer
JP2535134B2 (ja) * 1991-09-16 1996-09-18 ファイザー・インコーポレーテッド 縮合三環式窒素含有複素環
DK0613458T3 (da) * 1991-11-12 1998-02-09 Pfizer Acykliske ethylendiaminderivater som substans P receptorantagonister
EP0641328B1 (en) * 1992-05-18 2001-11-21 Pfizer Inc. Bridged aza-bicyclic derivatives as substance p antagonists
EP0654029A1 (en) * 1992-08-04 1995-05-24 Pfizer Inc. 3-benzylamino-2-phenyl-piperidine derivatives as substance p receptor antagonists
ATE208376T1 (de) * 1992-08-19 2001-11-15 Pfizer Substituierte benzylamin-stickstoff enthaltende nichtaromatische heterocyclen
ATE194340T1 (de) * 1992-12-10 2000-07-15 Pfizer Aminomethylen substituierte heterocyclische verbindungen und ihre verwendung alssubstanz p antagonisten
US5830854A (en) * 1992-12-14 1998-11-03 Merck Sharp & Dohme, Limited Method of treating cystic fibrosis using a tachykinin receptor antagonist
US5340826A (en) * 1993-02-04 1994-08-23 Pfizer Inc. Pharmaceutical agents for treatment of urinary incontinence
US5393762A (en) * 1993-06-04 1995-02-28 Pfizer Inc. Pharmaceutical agents for treatment of emesis
EP0655246A1 (en) * 1993-11-30 1995-05-31 Pfizer Inc. Substance P antagonists for the treatment of disorders caused by helicobacter pylori or other spiral urease-positive gram-negative bacteria
FR2725900B1 (fr) * 1994-10-21 1997-07-18 Sanofi Sa Utilisation d'antagonistes des recepteurs nk1 pour la preparation de medicaments a action cardioregulatrice
IL116249A (en) * 1994-12-12 2003-07-06 Pfizer Nk-1 receptor antagonists for the treatment of neuronal damage and stroke
GB9502582D0 (en) * 1995-02-10 1995-03-29 Smithkline Beecham Plc Novel process
GB9510459D0 (en) 1995-05-24 1995-07-19 Zeneca Ltd Bicyclic amines
WO1997043286A1 (en) * 1996-05-13 1997-11-20 Zeneca Limited Bicyclic amines as insecticides
ZA977103B (en) 1996-08-09 1999-02-08 Eisai Co Ltd Benzopiperidine derivatives
GB9623944D0 (en) * 1996-11-15 1997-01-08 Zeneca Ltd Bicyclic amine derivatives
GB9624114D0 (en) * 1996-11-20 1997-01-08 Zeneca Ltd Pesticidal bicyclic amine derivatives
GB9624611D0 (en) 1996-11-26 1997-01-15 Zeneca Ltd Bicyclic amine compounds
EA199900502A1 (ru) 1996-11-26 2000-02-28 Зенека Лимитед 8-азабицикло[3.2.1]октан-, 8-азабицикло[3.2.1]окт-6-ен-, 9-азабицикло[3.3.1]нонан-, 9-аза-3-оксабицикло[3.3.1]нонан- и 9-аза-3-тиабицикло[3.3.1]нонанпроизводные, их получение и их применение в качестве инсектицидов
US6982271B1 (en) 1999-09-27 2006-01-03 Georgetown University Tropane analogs
CA2324116A1 (en) * 1999-10-25 2001-04-25 Susan Beth Sobolov-Jaynes Nk-1 receptor antagonists and eletriptan for the treatment of migraine
US7163949B1 (en) 1999-11-03 2007-01-16 Amr Technology, Inc. 4-phenyl substituted tetrahydroisoquinolines and use thereof
CA2389306C (en) 1999-11-03 2010-03-30 Albany Molecular Research, Inc. Aryl- and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
BR0112350A (pt) 2000-07-11 2003-06-24 Albany Molecular Res Inc Composto, composição farmacêutica, e, método de tratar um animal afligido por um distúrbio neurológico ou psicológico
US20020049211A1 (en) * 2000-09-06 2002-04-25 Sobolov-Jaynes Susan Beth Combination treatment for depression and anxiety
EP1192952A3 (en) * 2000-09-28 2003-03-26 Pfizer Products Inc. Combination, for treating depression and anxiety, containing an NK-3 receptor antagonist and a CNS penetrant NK-1 receptor antagonist
AU2005274927B2 (en) 2004-07-15 2011-11-03 Albany Molecular Research, Inc. Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine, and serotonin
ATE550019T1 (de) 2005-05-17 2012-04-15 Merck Sharp & Dohme Cis-4-ä(4-chlorophenyl)sulfonylü-4-(2,5- difluorophenyl)cyclohexanepropansäure zur behandlug von krebs
JP5258561B2 (ja) 2005-07-15 2013-08-07 アルバニー モレキュラー リサーチ， インコーポレイテッド アリール置換およびヘテロアリール置換テトラヒドロベンズアゼピンならびにノルエピネフリン、ドーパミンおよびセロトニンの再取り込みを遮断するためのその使用
AU2006297443B2 (en) 2005-09-29 2010-08-12 Merck Sharp & Dohme Corp. Acylated spiropiperidine derivatives as melanocortin-4 receptor modulators
GB0603041D0 (en) 2006-02-15 2006-03-29 Angeletti P Ist Richerche Bio Therapeutic compounds
JP5489333B2 (ja) 2006-09-22 2014-05-14 メルク・シャープ・アンド・ドーム・コーポレーション 脂肪酸合成阻害剤を用いた治療の方法
US20110218176A1 (en) 2006-11-01 2011-09-08 Barbara Brooke Jennings-Spring Compounds, methods, and treatments for abnormal signaling pathways for prenatal and postnatal development
PL2805945T3 (pl) 2007-01-10 2019-09-30 Msd Italia S.R.L. Indazole podstawione grupą amidową jako inhibitory polimerazy poli(adp-rybozy) - (parp)
CN101641099A (zh) 2007-01-24 2010-02-03 葛兰素集团有限公司 包含3,5-二氨基-6-(2,3-二氯苯基)-1,2,4-三嗪或r(-)-2,4-二氨基-5-(2,3-二氯苯基)-6-氟甲基嘧啶和nk1的药物组合物
CA2682727C (en) 2007-04-02 2016-03-22 Banyu Pharmaceutical Co., Ltd. Indoledione derivative
CA2690191C (en) 2007-06-27 2015-07-28 Merck Sharp & Dohme Corp. 4-carboxybenzylamino derivatives as histone deacetylase inhibitors
CN102014631A (zh) 2008-03-03 2011-04-13 泰格尔医药科技公司 酪氨酸激酶抑制剂
AR071997A1 (es) 2008-06-04 2010-07-28 Bristol Myers Squibb Co Forma cristalina de 6-((4s)-2-metil-4-(2-naftil)-1,2,3,4-tetrahidroisoquinolin-7-il)piridazin-3-amina
US9156812B2 (en) 2008-06-04 2015-10-13 Bristol-Myers Squibb Company Crystalline form of 6-[(4S)-2-methyl-4-(2-naphthyl)-1,2,3,4-tetrahydroisoquinolin-7-yl]pyridazin-3-amine
UA105182C2 (ru) 2008-07-03 2014-04-25 Ньюрексон, Інк. Бензоксазины, бензотиазины и родственные соединения, которые имеют ингибирующую nos активность
EP2413932A4 (en) 2009-04-01 2012-09-19 Merck Sharp & Dohme INHIBITORS OF AKT ACTIVITY
CN102595902B (zh) 2009-05-12 2015-04-29 阿尔巴尼分子研究公司 7-([1,2,4]三唑并[1,5-a]吡啶-6-基)-4-(3,4-二氯苯基)-1,2,3,4-四氢异喹啉及其用途
ES2528404T3 (es) 2009-05-12 2015-02-10 Bristol-Myers Squibb Company Formas cristalinas de (S)-7-([1,2,4]triazol[1,5-a]piridin-6-il)-4-(3,4-diclorofenil)-1,2,3,4-tetrahidroisoquinolina y sus usos
WO2010132437A1 (en) 2009-05-12 2010-11-18 Albany Molecular Research, Inc. Aryl, heteroaryl, and heterocycle substituted tetrahydroisoquinolines and use thereof
NZ599343A (en) 2009-10-14 2014-05-30 Merck Sharp & Dohme Substituted piperidines that increase p53 activity and the uses thereof
EP2584903B1 (en) 2010-06-24 2018-10-24 Merck Sharp & Dohme Corp. Novel heterocyclic compounds as erk inhibitors
WO2012018754A2 (en) 2010-08-02 2012-02-09 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF CATENIN (CADHERIN-ASSOCIATED PROTEIN), BETA 1 (CTNNB1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP4079856A1 (en) 2010-08-17 2022-10-26 Sirna Therapeutics, Inc. Rna interference mediated inhibition of hepatitis b virus (hbv) gene expression using short interfering nucleic acid (sina)
EP2608669B1 (en) 2010-08-23 2016-06-22 Merck Sharp & Dohme Corp. NOVEL PYRAZOLO[1,5-a]PYRIMIDINE DERIVATIVES AS mTOR INHIBITORS
EP2613782B1 (en) 2010-09-01 2016-11-02 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
WO2012036997A1 (en) 2010-09-16 2012-03-22 Schering Corporation Fused pyrazole derivatives as novel erk inhibitors
ES2663009T3 (es) 2010-10-29 2018-04-10 Sirna Therapeutics, Inc. Inhibición de la expresión génica mediada por interferencia por ARN utilizando ácidos nucleicos de interferencia cortos (ANic)
EP2654748B1 (en) 2010-12-21 2016-07-27 Merck Sharp & Dohme Corp. Indazole derivatives useful as erk inhibitors
CA2831730A1 (en) 2011-04-21 2012-10-26 Piramal Enterprises Limited A crystalline form of a salt of a morpholino sulfonyl indole derivative and a process for its preparation
US9023865B2 (en) 2011-10-27 2015-05-05 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2013090260A1 (en) * 2011-12-12 2013-06-20 University Of Florida Research Foundation Nicotinic receptor targeted compounds and compositions
EP3453762B1 (en) 2012-05-02 2021-04-21 Sirna Therapeutics, Inc. Short interfering nucleic acid (sina) compositions
US9233979B2 (en) 2012-09-28 2016-01-12 Merck Sharp & Dohme Corp. Compounds that are ERK inhibitors
WO2014078568A1 (en) 2012-11-14 2014-05-22 The Johns Hopkins University Methods and compositions for treating schizophrenia
BR112015012295A8 (pt) 2012-11-28 2023-03-14 Merck Sharp & Dohme Uso de um inibidor de wee1, e, kit para identificar um paciente com câncer
BR112015013611A2 (pt) 2012-12-20 2017-11-14 Merck Sharp & Dohme composto, e, composição farmacêutica
US9540377B2 (en) 2013-01-30 2017-01-10 Merck Sharp & Dohme Corp. 2,6,7,8 substituted purines as HDM2 inhibitors
US20160194368A1 (en) 2013-09-03 2016-07-07 Moderna Therapeutics, Inc. Circular polynucleotides
JP6736661B2 (ja) * 2015-09-04 2020-08-05 ヤンセン ファーマシューティカ エヌ．ベー． 治療化合物及び合成
US10975084B2 (en) 2016-10-12 2021-04-13 Merck Sharp & Dohme Corp. KDM5 inhibitors
WO2019094311A1 (en) 2017-11-08 2019-05-16 Merck Sharp & Dohme Corp. Prmt5 inhibitors
EP3706747B1 (en) 2017-11-08 2025-09-03 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833668B1 (en) 2018-08-07 2025-03-19 Merck Sharp & Dohme LLC Prmt5 inhibitors
EP3833667B1 (en) 2018-08-07 2024-03-13 Merck Sharp & Dohme LLC Prmt5 inhibitors
AU2019317549A1 (en) 2018-08-07 2021-02-25 Msd International Gmbh PRMT5 inhibitors

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2455949A (en) * 1947-06-02 1948-12-14 Parke Davis & Co Dialkylaminoalkyl benzahydryl ethers and salts thereof
US3560510A (en) * 1969-03-05 1971-02-02 Aldrich Chem Co Inc 2-benzhydrylquinuclidines
GB1527489A (en) * 1976-08-05 1978-10-04 Andreu Sa Dr Amine compound
US4246201A (en) * 1979-06-11 1981-01-20 Alfa Farmaceutici, S.P.A. Substituted N-(3-phenylthiopropyl)-3,3-diphenyl-propylamines possessing pharmacological activity
MX18467A (es) * 1988-11-23 1993-07-01 Pfizer Agentes terapeuticos de quinuclidinas
UA41251C2 (uk) * 1990-01-04 2001-09-17 Пфайзер, Інк. Гідровані азотвмісні гетероциклічні сполуки, похідні піперидину, фармацевтична композиція та спосіб пригнічення активності речовини р в організмі
AU648317B2 (en) * 1990-06-01 1994-04-21 Pfizer Inc. 3-amino-2-aryl quinuclidines, process for their preparation and pharmaceutical compositions containing them
ATE116317T1 (de) * 1990-07-23 1995-01-15 Pfizer Chinuclidinderivate.

Also Published As

Publication number Publication date
NO302172B1 (no) 1998-02-02
DE69106365T2 (de) 1995-05-04
AU7894891A (en) 1992-02-18
DE69106365D1 (de) 1995-02-09
FI930262A0 (fi) 1993-01-22
US5821248A (en) 1998-10-13
NO930222L (no) 1993-01-22
PL167568B1 (pl) 1995-09-30
MX9100308A (es) 1992-02-28
NO930222D0 (no) 1993-01-22
DK0540526T3 (da) 1995-04-18
US5641786A (en) 1997-06-24
IL98860A0 (en) 1992-07-15
CA2086434A1 (en) 1992-01-24
ATE116317T1 (de) 1995-01-15
IE65000B1 (en) 1995-10-04
JPH05507687A (ja) 1993-11-04
ZA915727B (en) 1993-02-24
PT98393A (pt) 1992-05-29
PT98393B (pt) 1999-01-29
CA2086434C (en) 1998-09-22
MY107157A (en) 1995-09-30
FI930262L (fi) 1993-01-22
EP0540526A1 (en) 1993-05-12
FI114473B (fi) 2004-10-29
BR9106665A (pt) 1993-06-08
AU660416B2 (en) 1995-06-29
CN1058405A (zh) 1992-02-05
IL98860A (en) 1995-11-27
IE912560A1 (en) 1992-01-29
HU9300188D0 (en) 1993-04-28
GR3015144T3 (en) 1995-05-31
JP2514137B2 (ja) 1996-07-10
HUT62584A (en) 1993-05-28
EP0540526B1 (en) 1994-12-28
US5422354A (en) 1995-06-06
NZ239063A (en) 1995-09-26
YU128091A (sh) 1994-01-20
US5854256A (en) 1998-12-29
US5698568A (en) 1997-12-16
WO1992001688A1 (en) 1992-02-06

Similar Documents

Publication Publication Date Title
ES2065691T3 (es) Derivados de quinuclidina.
ES2132223T3 (es) Derivados de indol condensados en calidad de antagonistas del receptor 5-ht4.
ES2168260T3 (es) 3-aminoquinuclidinas sustituidas.
MX9307062A (es) Derivado de quinuclidina para el tratamiento de los trastornos inflamatorios y del sistema nervioso central.
MX9301634A (es) Quinuclidinas peptidicas.
ES2111650T3 (es) Derivados aciclicos de etilenodiamina como antagonistas de receptores de la sustancia p.
ES2188584T3 (es) Derivados heterociclicos de amina.
ES2040838T3 (es) Compuestos piperazinil-heterociclicos.
ES2113368T3 (es) Antagonistas de serotonina.
ES2084361T3 (es) Derivados de quinuclidina.
ES2153820T3 (es) Derivados de benzimidazol, procedimiento para su preparacion y aplicaciones.
MX9301197A (es) Derivados de indol.
ES2084339T3 (es) Tetrahidropiridinas e hidroxipiperidinas sustituidas utiles como agentes para el sistema nervioso central.
ES2181995T3 (es) Derivados de bencimidazol y uso como antagonistas del factor de liberacion de la corticotropina.
AR005102A1 (es) Compuestos derivados de octahidro-pirrolo [1,2-a]-pirazina 2,7-sustituidos, composiciones farmaceuticas y uso de dichos compuestos para la fabricacion deun medicamento.
ES2153842T3 (es) Derivados de 3-oxo-pirido(1,2-a-)bencimidazol-4-carboxilo y de 4-oxo-azepino(1,2-a)bencimidazol-5-carboxilo utiles en el tratamiento de enfermedades del sistema nervioso central.
ES2148600T3 (es) Derivados de indol sustituidos.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
ES2102019T3 (es) 2,3,4,5-tetrahidro-1h-3-benzazepinas y sus sales de adicion farmaceuticamente aceptables.
ES2087463T3 (es) Benzo(b)tiofen-2-carboxamidas para el tratamiento de trastornos del sistema nervioso central.
ES2055440T3 (es) Derivados del acido quinurenico, su preparacion y composiciones farmaceuticas que los contienen.
ES2088162T3 (es) Tienopirazina-2,3-dionas utiles para el tratamiento de enfermedades del sistema nervioso central, y su preparacion.
ECSP951595A (es) Derivados de pirrol case ran 4070/101
RU93004901A (ru) Хинуклидиновые производные, способ их получения, фармацевтическая композиция, способ лечения
UY23524A1 (es) Derivados del indol

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540526

Country of ref document: ES